BACKGROUND: Despite widespread promotion of quadrivalent human papillomavirus
(qHPV) vaccination for young girls, there is limited information on the vaccine's real-world …

BACKGROUND: Clinical trials of the 4-valent human papillomavirus (HPV) vaccine
demonstrate high efficacy, but surveillance studies are essential to examine the long-term …

Publicly funded administration of the quadrivalent HPV (qHPV) vaccine in school-aged girls
was implemented for all Canadian provinces and territories between 2007 and 2009 …

Background Although over a hundred million dollars have been invested in offering free
quadrivalent human papillomavirus (HPV) vaccination to young girls in Ontario, there …

BACKGROUND: Two vaccines against human papillomavirus (HPV), a necessary cause of
cervical cancer, are currently licensed and recommended for routine administration in the …

Background. Reducing the number of doses in the human papillomavirus (HPV) vaccination
regimen from 3 to 2 could increase coverage rates. In this cohort study, we assessed the risk …

OBJECTIVE: The goal was to describe factors associated with human papillomavirus (HPV)
vaccination series initiation (≥ 1 dose) and completion (≥ 3 doses) and parents' intent to …

* Quadrivalent HPV vaccine was licensed in 2006 (information available at http://www. cdc.
gov/mmwr/preview/mmwrhtml/rr5602a1. htm) and the bivalent HPV vaccine was licensed in …

BACKGROUND: Despite demonstrated effectiveness in real-world settings, concerns persist
regarding the safety of the quadrivalent human papillomavirus (HPV4) vaccine. We sought …

Background: Suboptimal human papillomavirus (HPV) vaccine coverage in some
jurisdictions is partly attributed to fears that vaccination may increase risky sexual behaviour …